These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 2393550)

  • 1. Polymorphic oxidation of debrisoquine in bladder cancer.
    Benítez J; Ladero JM; Fernández-Gundín MJ; Llerena A; Cobaleda J; Martínez C; Muñoz JJ; Vargas E; Prados J; González-Rozas F
    Ann Med; 1990 Jun; 22(3):157-60. PubMed ID: 2393550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetically determined debrisoquine oxidation capacity in bladder cancer.
    Cartwright RA; Philip PA; Rogers HJ; Glashan RW
    Carcinogenesis; 1984 Sep; 5(9):1191-2. PubMed ID: 6467507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Debrisoquine oxidation in a Finnish population: the effect of oral contraceptives on the metabolic ratio.
    Kallio J; Lindberg R; Huupponen R; Iisalo E
    Br J Clin Pharmacol; 1988 Dec; 26(6):791-5. PubMed ID: 3242585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence for the polymorphic oxidation of debrisoquine in the Thai population.
    Wanwimolruk S; Patamasucon P; Lee EJ
    Br J Clin Pharmacol; 1990 Feb; 29(2):244-7. PubMed ID: 2306417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxidative polymorphism of debrisoquine in Parkinson's disease.
    Benitez J; Ladero JM; Jimenez-Jimenez FJ; Martinez C; Puerto AM; Valdivielso MJ; Llerena A; Cobaleda J; Muñoz JJ
    J Neurol Neurosurg Psychiatry; 1990 Apr; 53(4):289-92. PubMed ID: 2341841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lung cancer risk, occupational exposure, and the debrisoquine metabolic phenotype.
    Caporaso N; Hayes RB; Dosemeci M; Hoover R; Ayesh R; Hetzel M; Idle J
    Cancer Res; 1989 Jul; 49(13):3675-9. PubMed ID: 2731181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antipyrine metabolism in relation to polymorphic oxidations of sparteine and debrisoquine.
    Eichelbaum M; Bertilsson L; Säwe J
    Br J Clin Pharmacol; 1983 Mar; 15(3):317-21. PubMed ID: 6849767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ifosfamide plasma clearance in relation to polymorphic debrisoquine oxidation.
    Philip PA; Lewis LD; James CA; Rogers HJ
    Cancer Chemother Pharmacol; 1988; 22(4):321-4. PubMed ID: 3168145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine.
    Bertilsson L; Dengler HJ; Eichelbaum M; Schulz HU
    Eur J Clin Pharmacol; 1980 Feb; 17(2):153-5. PubMed ID: 7371707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymorphism of the 4-hydroxylation of debrisoquine in the San Bushmen of southern Africa.
    Sommers DK; Moncrieff J; Avenant J
    Hum Toxicol; 1988 May; 7(3):273-6. PubMed ID: 3391625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metoprolol metabolism and debrisoquine oxidation polymorphism--population and family studies.
    McGourty JC; Silas JH; Lennard MS; Tucker GT; Woods HF
    Br J Clin Pharmacol; 1985 Dec; 20(6):555-66. PubMed ID: 2868742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic monooxygenase activities in subjects with a genetic defect in drug oxidation.
    Meier PJ; Mueller HK; Dick B; Meyer UA
    Gastroenterology; 1983 Sep; 85(3):682-92. PubMed ID: 6603386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities.
    Eichelbaum M; Bertilsson L; Säwe J; Zekorn C
    Clin Pharmacol Ther; 1982 Feb; 31(2):184-6. PubMed ID: 7056024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlations among the metabolic ratios of three test probes (metoprolol, debrisoquine and sparteine) for genetically determined oxidation polymorphism in a Japanese population.
    Horai Y; Taga J; Ishizaki T; Ishikawa K
    Br J Clin Pharmacol; 1990 Jan; 29(1):111-5. PubMed ID: 2297455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors.
    Kaisary A; Smith P; Jaczq E; McAllister CB; Wilkinson GR; Ray WA; Branch RA
    Cancer Res; 1987 Oct; 47(20):5488-93. PubMed ID: 3652049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymorphic oxidation of debrisoquine in lung cancer patients.
    Benítez J; Ladero JM; Jara C; Carrillo JA; Cobaleda J; Llerena A; Vargas E; Muñoz JJ
    Eur J Cancer; 1991; 27(2):158-61. PubMed ID: 1827280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Debrisoquine oxidation phenotype during neuroleptic monotherapy.
    Spina E; Martines C; Caputi AP; Cobaleda J; Piñas B; Carrillo JA; Benitez J
    Eur J Clin Pharmacol; 1991; 41(5):467-70. PubMed ID: 1684751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Altered distribution of debrisoquine oxidation phenotypes in patients with systemic lupus erythematosus.
    Baer AN; McAllister CB; Wilkinson GR; Woosley RL; Pincus T
    Arthritis Rheum; 1986 Jul; 29(7):843-50. PubMed ID: 3741500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic polymorphism of debrisoquine (CYP2D6) and proguanil (CYP2C19) in South Pacific Polynesian populations.
    Wanwimolruk S; Bhawan S; Coville PF; Chalcroft SC
    Eur J Clin Pharmacol; 1998 Jul; 54(5):431-5. PubMed ID: 9754989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic predisposition to Balkan endemic nephropathy: ability to hydroxylate debrisoquine as a host risk factor.
    Nikolov IG; Chernozemsky IN; Idle JR
    IARC Sci Publ; 1991; (115):289-96. PubMed ID: 1820343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.